Pasithea Therapeutics (NASDAQ:KTTA) Announces Earnings Results

Pasithea Therapeutics (NASDAQ:KTTA) announced its earnings results on Thursday. The company reported ($0.41) earnings per share for the quarter, FiscalAI reports.

Pasithea Therapeutics Stock Up 2.1%

NASDAQ:KTTA traded up $0.01 on Friday, reaching $0.72. The stock had a trading volume of 112,653 shares, compared to its average volume of 88,943. The company has a market capitalization of $5.34 million, a P/E ratio of -0.14 and a beta of 0.29. Pasithea Therapeutics has a 1-year low of $0.65 and a 1-year high of $3.85. The stock has a fifty day moving average price of $0.75 and a 200-day moving average price of $0.81.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pasithea Therapeutics stock. AdvisorShares Investments LLC raised its holdings in Pasithea Therapeutics Corp. (NASDAQ:KTTA) by 33.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 257,696 shares of the company’s stock after acquiring an additional 64,149 shares during the quarter. AdvisorShares Investments LLC owned approximately 3.46% of Pasithea Therapeutics worth $186,000 as of its most recent SEC filing. 23.92% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Pasithea Therapeutics in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.